
| Pipeline |
| Pipeline Status |
| Product Preclinical | P1 | P2 | P3 | NDA | Marketing |
| Nodlin |
| Nodexen |
| Nodlin |
| Insulin is the standard treatment for diabetic patients and requires multiple daily injection. Nodlin is an oral insulin formulation developed by Biolaxy based on NOD technology intended for basal insulin supplementation. |
| Nodexen |
| Exenatide is a first-in-class treatment for diabetes that requires twice daily injections. Nodexen is an oral exenatide formulation based on encapsulated nano-particles. This product has the potential to significantly reduce side effects and improve efficacy over conventional injections. |
| _____________________________________________________________________________________________________ © All rights reserved. 2005-10 Biolaxy |
